Clinical Trials at Swedish Cancer Institute
As of June 2026, 48 paid clinical trials are recruiting at Swedish Cancer Institute, located at 1221 MADISON ST, STE 150, SEATTLE, WA 98104-3588, phone (206) 215-6487 in Seattle, Washington. Active studies at this site cover conditions such as Acute Myeloid Leukemia, Breast Cancer and Colorectal Cancer. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
48 clinical trials at Swedish Cancer Institute
·Clear filters·↓ Download CSVAxillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers
Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis
A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
Early Chest Tube Removal After Surgery for Primary Spontaneous Pneumothorax: A Randomized Controlled Trial
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
Minimally Invasive Esophagectomy Pain Control Trial
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells
A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
About research studies in Seattle
Seattle has approximately 1,369 recruiting research studies across a wide range of therapeutic areas. Washington hosts Fred Hutchinson Cancer Center, UW Medicine, and Seattle Children's — widely recognized for leadership in bone marrow transplantation, immunotherapy, and infectious disease research.
Common conditions studied in Seattle
- Acute Myeloid Leukemia (33 active studies). Leukemia trials evaluate targeted inhibitors, CAR-T cell therapies, and novel combinations for acute and chronic forms of the disease.
- Breast Cancer (26 active studies). Breast cancer trials evaluate new hormone therapies, targeted drugs, and immunotherapy combinations aimed at improving survival and reducing recurrence.
- Colorectal Cancer (18 active studies). Colorectal cancer trials explore novel chemotherapy combinations, targeted agents, and immunotherapy for microsatellite-instability-high tumors.
- Ovarian Cancer (17 active studies). Ovarian cancer research examines PARP inhibitors, maintenance therapies, and antibody-drug conjugates for recurrent and platinum-resistant disease.
- Advanced Solid Tumor (16 active studies). Recruiting Advanced Solid Tumor studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
- Cancer (16 active studies). Recruiting Cancer studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
Leading research sponsors in Seattle
- University of Washington
- Fred Hutchinson Cancer Center
- National Cancer Institute (NCI)
- Seattle Children's Hospital
- AstraZeneca
Local regulations and guidelines
Clinical trials in Washington are governed by U.S. Food and Drug Administration (FDA) regulations, Office for Human Research Protections (OHRP) standards, and federal HIPAA privacy rules. Every study is reviewed by an Institutional Review Board (IRB) to protect participant safety and ensure informed consent. Studies in Washington must also comply with the My Health My Data Act, which adds consumer-health-data protections on top of federal HIPAA requirements.
Compensation & what to expect
- How payment typically works
- Compensation is most often provided through reloadable electronic study cards or direct deposit, paid out per completed visit rather than as a lump sum. Amounts vary by the time required, the number of visits, and the study's complexity — overnight stays and inpatient pharmacology studies generally pay more than short outpatient surveys. The exact amount is disclosed in writing during informed consent before any visit.
- Healthy volunteers
- Healthy participants aged 18 and older can earn compensation by joining vaccine, pharmacology, and biomarker studies in Seattle. These trials check how a new drug or vaccine behaves in healthy bodies before later-phase testing. Many sites maintain a healthy-volunteer registry so you hear about new opportunities first.
- What's included beyond payment
- Most trials cover study-related medical care at no cost — physical exams, lab work, imaging, the investigational treatment itself, and follow-up visits with the research team. Insurance is not required to participate. Free check-ups and access to specialists are common reasons participants return for additional studies.
- Travel and time
- Many sponsors reimburse travel, parking, mileage, and lost wages for visit days. Long-running studies and trials that require frequent visits often raise stipends accordingly. Ask the study coordinator for the visit schedule and reimbursement policy before you commit.
- Asking about compensation
- Compensation is set per protocol and per site, so figures are not published in trial registries. The fastest way to confirm payment for a specific study is to contact the recruiting site listed on the study record. Coordinators are accustomed to this question and will quote the per-visit and total amounts up front.
How to find a clinical trial in Seattle
Hipa.ai aggregates every recruiting study in Seattle from ClinicalTrials.gov and refreshes the list daily. Use the filters above to narrow by condition, facility, age, phase, or healthy-volunteer eligibility, then click any study title to view full details — eligibility criteria, intervention, location, and sponsor contact information. To enroll, reach out to the central study contact listed on the study detail page; the research coordinator will walk you through the screening process.
Frequently asked questions
How many paid clinical trials are currently recruiting in Seattle?
There are approximately 1,369 recruiting clinical trials in Seattle, Washington listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Seattle pay participants?
Most recruiting trials in Seattle compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Seattle?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Seattle?
The most common conditions under active study in Seattle include Acute Myeloid Leukemia (33), Breast Cancer (26), Colorectal Cancer (18), Ovarian Cancer (17), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Seattle?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Seattle on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Seattle?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Seattle?
Recruiting research sites in Seattle include University of Washington, Seattle Children's Hospital, Fred Hutchinson Cancer Center, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Seattle right now?
The largest active categories in Seattle are Cancer & tumors (528), Neurology & pain (71), Diabetes & metabolic (57). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of Swedish Cancer Institute?
Swedish Cancer Institute is located at 1221 MADISON ST, STE 150, SEATTLE, WA 98104-3588. Use the Google Maps link in the intro above to get directions.
How do I contact Swedish Cancer Institute?
You can reach Swedish Cancer Institute by phone at (206) 215-6487. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.